Medimaps Group
Medimaps Group is a Swiss med-tech company that develops AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment using its proprietary Trabecular Bone Score (TBS) technology, serving healthcare providers, radiology departments, and pharmaceutical companies across 90 markets.
- Company typePrivate
- Founded2006
- HeadquartersPlan-les-ouates, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Medimaps Group does
Medimaps Group S.A. is a Swiss med-tech company founded in 2006 and headquartered in Plan-les-Ouates, Geneva, developing AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment. The company's core technology is its proprietary TBS iNsight deep-tech platform, which applies computer vision and predictive analytics to DXA bone densitometry scans to evaluate trabecular bone structure beyond what standard bone mineral density (BMD) measurements capture. The product portfolio is anchored by TBS Osteo (DXA-based fracture risk assessment), expanded in December 2025 with TBS Reveal (X-ray-based opportunistic bone fragility screening), and complemented by TBS Ortho (orthopedic applications). The company also offers CRO services to pharmaceutical companies for bone-health clinical trials.
The company operates a subscription-based software licensing model with quote-based enterprise pricing, supported by 4 dedicated Medicare CPT reimbursement codes in the United States that have seen steadily increasing reimbursement under the Physician Fee Schedule and Outpatient Prospective Payment System. Distribution combines direct enterprise field sales (with a 'Book a demo' motion) and OEM channel partnerships with the three dominant global DXA hardware manufacturers — GE HealthCare, Hologic, and OsteoSys. The technology is FDA 510(k) cleared, CE-marked under EU MDR (notified body 2460), and ISO 13485:2016 certified, with 1,500 peer-reviewed publications and 35 clinical guidelines referencing TBS technology, and approximately 4.5 million TBS procedures performed annually across 90 markets.
In March 2026, Medimaps announced a strategic merger with Copenhagen-based Radiobotics ApS to create the world's first end-to-end musculoskeletal AI ecosystem combining preventive bone-health assessment with trauma-related fracture detection (RBfracture). The combined entity will operate across 90 markets with offices in Geneva (HQ), Wilmington, Delaware, and Copenhagen, leveraging Medimaps' US office for FDA clearance of RBfracture and Radiobotics' Danish office for streamlined CE registration. The transaction remains subject to Danish foreign direct investment approval. Medimaps is privately held, having raised USD 20 million in December 2021 from Swisscanto, Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures, and has a headcount in the 11-50 range.
Medimaps Group firmographics
Firmographics- Name
- Medimaps Group
- Legal name
- Medimaps Group S.A.
- Website
- https://medimapsgroup.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medimaps Group is a Swiss med-tech company that develops AI-powered imaging software for bone microarchitecture analysis and fracture risk assessment using its proprietary Trabecular Bone Score (TBS) technology, serving healthcare providers, radiology departments, and pharmaceutical companies across 90 markets.
- Ownership category
- akta.pro rank
Medimaps Group industry classification
Industry- Product category
- Medical Imaging Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where Medimaps Group is headquartered
LocationHeadquarters
- HQ city
- Plan-les-ouates
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
Medimaps Group business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- TBS Osteo Software Licensing: AI-powered bone microarchitecture analysis software licensed to healthcare providers for use during DXA bone densitometry scans. Benefits from 4 dedicated CPT codes for Medicare beneficiaries with steadily increasing reimbursement under PFS and OPPS in the USA.
- TBS Reveal (X-ray opportunistic screening): AI-powered software for opportunistic screening using X-ray technology, enabling additional revenue stream from routine X-ray imaging analysis.
- CRO Services for Pharma: Contract research organization services provided to pharmaceutical companies, likely for clinical trials involving bone health therapeutics.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Medimaps Group product offering
Product offeringCore offering
Medimaps Group develops and commercializes AI-powered medical imaging software that analyzes bone microarchitecture from DXA bone densitometry scans and routine X-rays to predict osteoporosis fracture risk. Its proprietary TBS iNsight platform powers TBS Osteo (DXA-based assessment), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), with native integration into GE HealthCare, Hologic, and OsteoSys DXA systems. The company also offers contract research organization (CRO) services to pharmaceutical clients for bone health clinical trials.
Product overview
Medimaps Group offers a unified portfolio of AI-powered bone health imaging solutions centered on its proprietary TBS (Trabecular Bone Score) technology platform. The core offering includes TBS Osteo (DXA-based bone microarchitecture analysis), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), all powered by the TBS iNsight deep-tech platform. The company also provides CRO services for pharmaceutical research. Following the 2026 merger with Radiobotics, the portfolio expanded to include trauma-related fracture detection (RBfracture), creating an end-to-end musculoskeletal AI ecosystem spanning preventive care and acute fracture assessment across X-ray and DXA modalities. The technology is integrated with major DXA hardware platforms (GE HealthCare, Hologic, Osteosys) and is deployed across 90 countries with reimbursement support in the United States.
Differentiator
Problem solved
Functional benefit
Brands
- TBS Osteo: AI-ready technology and state-of-the-art software powered by TBS iNsight to evaluate bone microarchitecture in patients during DXA bone densitometry scan for osteoporosis fracture risk assessment.
- TBS Ortho
- TBS Reveal
- CRO services for pharma
Quantifiable outcome
- 4.5M worldwide procedures/year using TBS technology
- +3 more outcomes
Companies that use Medimaps Group
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Medimaps Group technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature4 records
Medimaps Group partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Radiobotics ApScoreStrategic merger agreement to create world's first end-to-end MSK AI ecosystem combining bone microarchitecture analysis with trauma-related fracture detection. Combined entity will serve 90 markets worldwide. Radiobotics will leverage Medimaps' U.S. office for FDA clearance; Medimaps will use Radiobotics' Danish office for CE registration. Transaction subject to Danish FDI approval.
- GE HealthCaremajorGlobal DXA partner displaying Medimaps' TBS technology integration with GE HealthCare bone densitometry systems.
- HologicmajorGlobal DXA partner displaying Medimaps' TBS technology integration with Hologic bone densitometry systems.
- OsteoSysmajorGlobal DXA partner displaying Medimaps' TBS technology integration with OsteoSys bone densitometry systems.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Medimaps Group competitors and assessment
Company assessmentDirect peers
- Radiobotics: Denmark-based AI medical imaging company developing RBfracture, an AI-powered fracture detection solution for trauma X-ray. Radiobotics is the announced merger partner of Medimaps Group, making it the closest direct peer in MSK AI imaging on the trauma-detection side.
- Gleamer: AI medical imaging company best known for BoneView, an AI fracture detection solution on routine X-ray. Highly comparable to Medimaps on AI-enabled bone imaging, with overlapping MSK use cases and radiology customer base.
Broad incumbents
- GE HealthCare: Global medical imaging and DXA equipment manufacturer that integrates or distributes Medimaps' TBS software alongside its bone densitometry hardware. A broad incumbent that overlaps with Medimaps in the bone-health workflow while also serving a far wider imaging portfolio.
- Hologic: Major women's health and DXA manufacturer whose bone densitometry systems integrate with Medimaps' TBS technology. Comparable as a DXA channel partner and broader incumbent in bone health diagnostics.
- Lunit: South Korea-based AI medical imaging company with FDA-cleared solutions across cancer detection and chest X-ray. Comparable as an established AI imaging vendor with regulatory clearances and global distribution, though focused outside MSK.
- Aidoc: AI medical imaging platform serving hospitals with FDA-cleared algorithms across multiple body parts and modalities. Comparable as a broad AI imaging incumbent pursuing enterprise health-system deals in the same clinical buyer base.
- Qure.ai: AI medical imaging company with FDA-cleared solutions across chest X-ray, head CT, and musculoskeletal imaging. Comparable as a multi-modality AI imaging vendor with regulatory clearances targeting similar radiology customers.
Emerging players
- Annalise.ai: AI medical imaging company providing comprehensive X-ray and CT decision-support tools, with a fracture and MSK module. Comparable as an emerging AI imaging player with overlapping bone-related use cases on routine X-ray.
- CurveBeam AI: AI-focused orthopedic and bone imaging company developing 3D and weight-bearing CT imaging solutions. Comparable as an emerging player in AI-driven bone and MSK imaging targeting orthopedic and radiology customers.
Regional players
- OsteoSys: South Korea-based DXA bone densitometry manufacturer that integrates and distributes Medimaps' TBS software. Comparable as a regional DXA partner with strong Asia-Pacific presence, distinct from GE HealthCare and Hologic's global footprint.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Medimaps Group social profiles
Digital presenceMedimaps Group compliance and trust
Trust signalCompliance3 records
Medimaps Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medimaps Group leadership team
Management profileNumber of profiles
Medimaps Group subsidiaries and ownership
Company hierarchySubsidiaries1 record
Medimaps Group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medimaps Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medimaps Group
What does Medimaps Group do?
Medimaps Group develops and commercializes AI-powered medical imaging software that analyzes bone microarchitecture from DXA bone densitometry scans and routine X-rays to predict osteoporosis fracture risk. Its proprietary TBS iNsight platform powers TBS Osteo (DXA-based assessment), TBS Reveal (X-ray opportunistic screening), and TBS Ortho (orthopedic applications), with native integration into GE HealthCare, Hologic, and OsteoSys DXA systems. The company also offers contract research organization (CRO) services to pharmaceutical clients for bone health clinical trials.
Is Medimaps Group a public or private company?
Medimaps Group is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medimaps Group founded?
Medimaps Group was founded in 2006. It employs 11 to 50 people.
Where is Medimaps Group based?
Medimaps Group is headquartered in Plan-les-ouates, Switzerland, in the Europe region.
How does Medimaps Group make money?
Three revenue lines are on record. TBS Osteo Software Licensing is the primary driver. The others are TBS Reveal (X-ray opportunistic screening) and CRO Services for Pharma.
Who are Medimaps Group's main competitors?
Direct peers on record are Radiobotics and Gleamer. Broad incumbents are GE HealthCare, Hologic, Lunit, Aidoc and Qure.ai. Emerging players are Annalise.ai and CurveBeam AI. OsteoSys is listed as a regional player.
Does Medimaps Group have an API?
No public API is recorded for Medimaps Group.
What industry is Medimaps Group in?
Medimaps Group's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 541714 and its SIC code is 3841.